Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cyclo Therapeutics, Inc.CYTH · Entity 82635 | Director | February 27, 2025 | March 03, 2025 |
| Rafael Holdings, Inc.RFL · Entity 6620 | Director | January 28, 2026 | January 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cyclo Therapeutics, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 440,260 |
Reported balance
After 2025-02-27 transaction · row 1
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 58,138 · Balance 440,260 F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025.
Rafael Holdings, Inc.
Report date January 28, 2026 · Filed January 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common Stock, par value $.01 per shareSEC Table I · non-derivative | Direct | 219,710 |
Reported balance
After 2026-01-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-28 · Grant · Acquired 29,528 · Balance 219,710 F1: Grant of Restricted Stock that vests in full immediately. F2: Represents the average closing price of the Issuer's Class B common stock during December 2025. F3: Consists of 29,528 fully vested shares of Restricted Stock and 190,182 shares held directly. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of Restricted Stock that vests in full immediately.
F2: Represents the average closing price of the Issuer's Class B common stock during December 2025.
F3: Consists of 29,528 fully vested shares of Restricted Stock and 190,182 shares held directly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2026 Filed Jan 30, 2026 16:01 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | GrantClass B Common Stock, par value $.01 per share | 29,528 | $1.27 | $37,500.56 |
DisclosureSEC source: 0001193125-26-031749 · ownership.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,710 F1 · shares: Grant of Restricted Stock that vests in full immediately. F2 · price: Represents the average closing price of the Issuer's Class B common stock during December 2025. F3 · balance_after: Consists of 29,528 fully vested shares of Restricted Stock and 190,182 shares held directly. Read SEC document |
| May 27, 2025 Filed May 29, 2025 15:04 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | OtherSubscription Rights (right to buy) · Derivative | 35,000 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0000950170-25-078854 · ownership.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 35,000 shares Expires 2025-05-29 Read SEC document |
| May 27, 2025 Filed May 29, 2025 15:04 UTC | Rafael Holdings, Inc. RFL · Entity 6620 | OtherClass B Common Stock, par value $.01 per share | 35,000 | $1.28 | $44,800.00 |
DisclosureSEC source: 0000950170-25-078854 · ownership.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,182 F1 · shares: Represents the exercise of subscription rights in the Issuer's Rights Offering. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 11:42 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 58,138 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-005846 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,260 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025. The number of shares received in lieu of cash was calculated based on the closing price of $0.77 per share of common stock on February 26, 2025. Read SEC document |
| November 15, 2024 Filed Nov 18, 2024 14:10 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 35,022 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-035586 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 382,122 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $0.66 per share of common stock on November 14, 2024. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 13:47 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 18,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-027326 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,100 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.26 per share of common stock on August 16, 2024. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:10 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to Buy) · Derivative | 15,562 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-24-019348 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,562 Underlying: Common Stock · 15,562 shares Expires 2034-06-03 F2 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 17:10 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 18,067 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-019348 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 328,746 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the first quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.28 per share of common stock on June 3, 2024. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 16:46 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 14,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004388 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,679 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.58 per share of common stock on February 13, 2024. Read SEC document |
| November 28, 2023 Filed Nov 30, 2023 09:05 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 16,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-033216 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,675 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.34 per share of common stock on November 28, 2023. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 65,869 | Not disclosed Strike: $0.95 | Not disclosed |
DisclosureSEC source: 0001437749-23-028702 · rdgdoc.xml · derivative · entry 3 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,869 Underlying: Common Stock · 65,869 shares Expires 2027-10-20 F1 · price: The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 59,881 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | OtherWarrant to Purchase Common Stock · Derivative | 59,881 | $0.13 Strike: $0.71 | $7,485.13 |
DisclosureSEC source: 0001437749-23-028702 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 59,881 shares Expires 2030-04-20 Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 06:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | OtherCommon Stock | 59,881 | $0.71 | $42,515.51 |
DisclosureSEC source: 0001437749-23-028702 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,163 F1 · kind: The Reporting Person exercised vested Warrants (the "Original Warrants") to purchase 59,881 shares of the Issuer's common stock pursuant to a Securities Purchase Agreement dated October 20, 2023 ("Closing Date"). The Reporting Person exercised his Original Warrant in full on or prior to the Closing Date in consideration of the receipt of new warrants with an exercise price equal to $0.95 per share, to purchase 110% of the shares of the Issuer's common stock covered under the Original Warrants. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 16:06 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 16,269 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-024415 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,282 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of $1.36 per share of common stock on August 18, 2023. Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:39 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 42,962 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-015129 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,013 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2022 and first quarter of 2023. The number of shares received in lieu of cash was calculated based on the closing price of 1.03 per share of common stock on May 16, 2023. Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:27 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 59,881 | $0.13 Strike: $0.71 | $7,485.13 |
DisclosureSEC source: 0001437749-23-010876 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,881 Underlying: Common Stock · 59,881 shares Expires 2030-04-20 Read SEC document |
| April 20, 2023 Filed Apr 24, 2023 10:27 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 59,881 | $0.71 | $42,515.51 |
DisclosureSEC source: 0001437749-23-010876 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,051 Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 17:08 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 3,350 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001437749-23-006000 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,350 Underlying: Common Stock · 3,350 shares Expires 2033-03-07 F1 · derivative.exercise_date: The option vests over a one year period in equal quarterly installments. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 16:02 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 9,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-026585 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,170 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the third quarter of 2022. The number of shares received in lieu of cash was calculated based on the closing price of 1.17 per share of common stock on November 7, 2022. Read SEC document |
| August 02, 2022 Filed Aug 4, 2022 16:03 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 5,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-018880 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,674 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the second quarter of 2022. The number of shares received in lieu of cash was calculated based on the closing price of 1.92 per share of common stock on August 1, 2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 21:27 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 4,223 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-010957 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,912 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the first quarter of 2022. The number of shares received in lieu of cash was calculated based on the closing price of 2.62 per share of common stock on May 2, 2022. Read SEC document |
| March 29, 2022 Filed Mar 30, 2022 10:28 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 10,000 | $2.73 | $27,300.00 |
DisclosureSEC source: 0001437749-22-007616 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,689 Read SEC document |
| January 28, 2022 Filed Feb 1, 2022 09:23 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantCommon Stock | 4,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-002054 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,689 F1 · price: Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's non-employee director compensation policy. Grant reflects director compensation for the fourth quarter of 2021. The number of shares received in lieu of cash was calculated based on the closing price of 3.62 per share of common stock on January 28, 2022. Read SEC document |
| August 27, 2021 Filed Aug 30, 2021 19:03 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | GrantStock Option (Right to buy) · Derivative | 6,700 | $0.00 Strike: $7.46 | $0.00 |
DisclosureSEC source: 0001437749-21-021209 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,700 Underlying: Common Stock · 6,700 shares Expires 2031-08-27 Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 09:14 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 2,500 | $6.00 Strike: $5.00 | $15,000.00 |
DisclosureSEC source: 0001437749-21-015195 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 2,500 shares Expires 2025-12-11 Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 09:14 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 7,500 | $6.50 Strike: $5.00 | $48,750.00 |
DisclosureSEC source: 0001437749-21-015195 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 7,500 shares Expires 2025-12-11 Read SEC document |
| May 21, 2021 Filed May 24, 2021 11:08 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 3,482 | $3.65 Strike: $5.00 | $12,709.30 |
DisclosureSEC source: 0001437749-21-013106 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 3,482 shares Expires 2025-12-11 F1 · price: The price reported is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $3.55 to $3.90, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of warrants purchased at each separate price within the foregoing ranges. Read SEC document |
| May 20, 2021 Filed May 21, 2021 11:54 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 2,312 | $3.19 Strike: $5.00 | $7,375.28 |
DisclosureSEC source: 0001437749-21-013021 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,518 Underlying: Common Stock · 2,312 shares Expires 2025-12-11 Read SEC document |
| May 19, 2021 Filed May 21, 2021 11:54 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 9,206 | $3.01 Strike: $5.00 | $27,710.06 |
DisclosureSEC source: 0001437749-21-013021 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,206 Underlying: Common Stock · 9,206 shares Expires 2025-12-11 F1 · price: The price reported is a weighted average price. These Warrants were purchased in multiple transactions at prices ranging from $2.79 to $3.20, inclusive. The reporting person undertakes to provide to the Issuer and the staff of the Securities and Exchange Commission, on request, full information regarding the number of warrants purchased at each separate price within the foregoing ranges. Read SEC document |
| March 29, 2021 Filed Mar 30, 2021 13:26 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 10,000 | $8.10 | $81,000.00 |
DisclosureSEC source: 0001437749-21-007619 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,614 Read SEC document |
| January 26, 2021 Filed Jan 27, 2021 08:36 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 2,201 | $6.60 | $14,526.60 |
DisclosureSEC source: 0001437749-21-001338 · rdgdoc.xml · nonDerivative · entry 4 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,614 Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 08:36 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 3,400 | $6.36 | $21,624.00 |
DisclosureSEC source: 0001437749-21-001338 · rdgdoc.xml · nonDerivative · entry 3 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,413 Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 08:36 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 1,400 | $6.35 | $8,890.00 |
DisclosureSEC source: 0001437749-21-001338 · rdgdoc.xml · nonDerivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,013 Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 08:36 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 2,999 | $6.20 | $18,593.80 |
DisclosureSEC source: 0001437749-21-001338 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,613 F1 · balance_after: Since the date of the reporting person's last ownership report, the reporting person transferred 25,115 shares of Common Stock to his former spouse pursuant to a domestic relations order, and does not beneficially own any of such shares. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:03 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 15,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-20-025286 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2025-12-11 F1 · price: The reported securities consist of 15,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 11, 2020 Filed Dec 14, 2020 16:03 UTC | Cyclo Therapeutics, Inc. CYTH · Entity 82635 | PurchaseCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-025286 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,729 F1 · price: The reported securities consist of 15,000 "Units" purchased by the reporting person for $5.00 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 09:26 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 750,000 | Not disclosed Strike: $0.15 | Not disclosed |
DisclosureSEC source: 0001437749-20-018982 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2027-08-27 F1 · price: The reported securities consist of 750,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 09:26 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 750,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-20-018982 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,772,857 F1 · price: The reported securities consist of 750,000 "Units" purchased by the reporting person for $0.10 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 16:05 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 500,000 | $0.10 | $50,000.00 |
DisclosureSEC source: 0001437749-20-008575 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,022,857 Read SEC document |
| August 23, 2019 Filed Aug 26, 2019 16:04 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | $0.22 | $22,000.00 |
DisclosureSEC source: 0001437749-19-017442 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,522,857 Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:35 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 400,000 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001437749-19-011249 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2024-11-30 F1 · price: The reported securities consist of 400,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 14:35 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 400,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-011249 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,422,857 F1 · price: The reported securities consist of 400,000 "Units" purchased by the reporting person for $0.25 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 10:27 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 100,000 | Not disclosed Strike: $0.65 | Not disclosed |
DisclosureSEC source: 0001437749-18-022633 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-12-21 F1 · price: The reported securities consist of 100,000 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| December 21, 2018 Filed Dec 27, 2018 10:27 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseCommon Stock | 100,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-022633 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,022,857 F1 · price: The reported securities consist of 100,000 "Units" purchased by the reporting person for $0.65 per Unit. Each Unit consists of one share of Common Stock and a warrant to purchase one share of Common Stock. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionSeries B Convertible Preferred Stock · Derivative | 500 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-012611 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F1 · derivative.expiration_date: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 23, 2018 Filed Jun 28, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | ConversionCommon Stock | 200,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-012611 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,922,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the automatic conversion of Series B Convertible Preferred Stock ("Series B Preferred") into Common Stock upon the filing of Articles of Amendment to the Issuer's Articles of Incorporation increasing the Issuer's authorized shares of Common Stock. The conversion is an exempt transaction pursuant to Rule 16b-7 under the Securities Exchange Act of 1934, as amended. F2 · price: The Series B Preferred were included in "Units" purchased by the reporting person for $100 per Unit. Each Unit consisted of one share of Series B Preferred convertible into 400 shares of Common Stock and one warrant to purchase 400 shares of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 100,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-007689 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2025-04-23 F2 · price: The reported securities consist of 250 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. Read SEC document |
| April 23, 2018 Filed Apr 25, 2018 16:02 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseSeries B Convertible Preferred Stock · Derivative | 250 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-18-007689 · rdgdoc.xml · derivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 100,000 shares Expires not disclosed F2 · price: The reported securities consist of 250 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. F1 · derivative.exercise_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. F1 · derivative.expiration_date: The Series B Convertible Preferred Stock ("Series B Preferred") will automatically convert into Common Stock on the date the Issuer effects an increase of its authorized shares of Common Stock and/or a reverse stock split so that it has a sufficient number of authorized and unissued shares of Common Stock to permit the conversion or exercise, as applicable of all outstanding shares of Series B Preferred, warrants, options and other convertible securities of the Issuer. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 16:28 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-001676 · rdgdoc.xml · nonDerivative · entry 1 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,722,857 Read SEC document |
| October 18, 2017 Filed Oct 19, 2017 16:01 UTC | Cyclo Therapeutics, Inc. CTDH · Entity 82635 | PurchaseWarrant to Purchase Common Stock · Derivative | 100,000 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001437749-17-017325 · rdgdoc.xml · derivative · entry 2 Sieger Markus · CIK 0001337143 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-10-18 F2 · price: The reported securities consist of 250 "Units" purchased by the reporting person for $100 per Unit. Each Unit consists of one share of Series B Preferred and warrants to purchase 400 shares of Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.